Who owns Relay Therapeutics, Inc. (RLAY)? Elite investor 13F holders
2 tracked elite investors reported holding Relay Therapeutics, Inc as of 2026-06-30, including Alphabet, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alphabet | RELAY THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 26381643.00 USD | 1410029.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | RELAY THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 3599785.00 USD | 192399.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | RELAY THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.